Loading…

Contribution of drug transport and reductases to daunorubicin resistance in human myelocytic cells

We developed three daunorubicin (D1)-resistant sublines (ML1/I, II, III) from the human myelocytic cell line (ML1). These sublines were 28-, 70- and 162-fold more resistant than sensitive (ML1/S) cells to the cytotoxicity of D1 and were cross-resistant to adriamycin, epiadriamycin, actinomycin D, VP...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology 1986-01, Vol.18 (2), p.105-110
Main Authors: VASANTHAKUMAR, G, AHMED, N. K
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c311t-d7f7a063511b0d3073cd07305ba3ed110cf5caea71da18348a017807ab0953b03
cites
container_end_page 110
container_issue 2
container_start_page 105
container_title Cancer chemotherapy and pharmacology
container_volume 18
creator VASANTHAKUMAR, G
AHMED, N. K
description We developed three daunorubicin (D1)-resistant sublines (ML1/I, II, III) from the human myelocytic cell line (ML1). These sublines were 28-, 70- and 162-fold more resistant than sensitive (ML1/S) cells to the cytotoxicity of D1 and were cross-resistant to adriamycin, epiadriamycin, actinomycin D, VP-16, VM26, and mitoxantrone. Steady-state levels of D1 in resistant sublines I and II, in the presence or absence of azide, were not significantly different from those of sensitive cells. However, the steady-state level of D1 in subline III was significantly increased in the presence of sodium azide. D1 efflux was minimal in ML1/S and resistant cells in the absenced of glucose. Addition of glucose enhanced D1 efflux only in subline III. Verapamil increased the cellular levels of D1 and inhibited its efflux from resistant III cells but not from ML1/S cells. Verapamil also greatly enhanced the cytotoxicity of D1 for sublines I, II, and III. The differences between sensitive and resistant cells in D1 uptake and retention seemed inadequate to cause 162-fold resistance and suggested other factors may be contributing to the development of resistance. In support of this hypothesis, daunorubicin reductase activity was significantly lower in resistant cells than in ML1/S cells. The greatest decrease in activity occurred at pH 8.5 which represents aldehyde reductases. Currently, we are investigating other possibilities for D1 metabolism, such as aglycone and free radical formation.
doi_str_mv 10.1007/BF00262277
format article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF00262277</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3539383</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-d7f7a063511b0d3073cd07305ba3ed110cf5caea71da18348a017807ab0953b03</originalsourceid><addsrcrecordid>eNpFkE1Lw0AQhhdRaq1evAt78CREZzNJNzlqsSoUvOg5zH5EV5Js2d0c-u-NtNTLvAzvwww8jF0LuBcA8uFpDZAv81zKEzYXBeYZVAWesjlgUWSlhOKcXcT4AwCFQJyxGZZYY4VzplZ-SMGpMTk_cN9yE8YvngINcetD4jQYHqwZdaJoI0-eGxoHH0bltBumKrqYaNCWT9v32NPA-53tvN4lp7m2XRcv2VlLXbRXh1ywz_Xzx-o127y_vK0eN5lGIVJmZCsJllgKocAgSNRmGlAqQmuEAN2WmixJYUhUWFQEQlYgSUFdogJcsLv9XR18jMG2zTa4nsKuEdD8eWr-PU3wzR7ejqq35ogexEz97aGnqKlrJyHaxSMm63o5vcdfIKZwYQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Contribution of drug transport and reductases to daunorubicin resistance in human myelocytic cells</title><source>Springer Online Journal Archives (Through 1996)</source><creator>VASANTHAKUMAR, G ; AHMED, N. K</creator><creatorcontrib>VASANTHAKUMAR, G ; AHMED, N. K</creatorcontrib><description>We developed three daunorubicin (D1)-resistant sublines (ML1/I, II, III) from the human myelocytic cell line (ML1). These sublines were 28-, 70- and 162-fold more resistant than sensitive (ML1/S) cells to the cytotoxicity of D1 and were cross-resistant to adriamycin, epiadriamycin, actinomycin D, VP-16, VM26, and mitoxantrone. Steady-state levels of D1 in resistant sublines I and II, in the presence or absence of azide, were not significantly different from those of sensitive cells. However, the steady-state level of D1 in subline III was significantly increased in the presence of sodium azide. D1 efflux was minimal in ML1/S and resistant cells in the absenced of glucose. Addition of glucose enhanced D1 efflux only in subline III. Verapamil increased the cellular levels of D1 and inhibited its efflux from resistant III cells but not from ML1/S cells. Verapamil also greatly enhanced the cytotoxicity of D1 for sublines I, II, and III. The differences between sensitive and resistant cells in D1 uptake and retention seemed inadequate to cause 162-fold resistance and suggested other factors may be contributing to the development of resistance. In support of this hypothesis, daunorubicin reductase activity was significantly lower in resistant cells than in ML1/S cells. The greatest decrease in activity occurred at pH 8.5 which represents aldehyde reductases. Currently, we are investigating other possibilities for D1 metabolism, such as aglycone and free radical formation.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/BF00262277</identifier><identifier>PMID: 3539383</identifier><identifier>CODEN: CCPHDZ</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Adult ; Alcohol Oxidoreductases - analysis ; Aldehyde Reductase ; Aldo-Keto Reductases ; Antineoplastic agents ; Biological and medical sciences ; Biological Transport ; Cell Line ; Daunorubicin - metabolism ; Daunorubicin - pharmacology ; Drug Resistance ; Drug Synergism ; General aspects ; Humans ; Leukemia, Myeloid - metabolism ; Medical sciences ; Pharmacology. Drug treatments ; Verapamil - pharmacology</subject><ispartof>Cancer chemotherapy and pharmacology, 1986-01, Vol.18 (2), p.105-110</ispartof><rights>1987 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c311t-d7f7a063511b0d3073cd07305ba3ed110cf5caea71da18348a017807ab0953b03</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=7996017$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3539383$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>VASANTHAKUMAR, G</creatorcontrib><creatorcontrib>AHMED, N. K</creatorcontrib><title>Contribution of drug transport and reductases to daunorubicin resistance in human myelocytic cells</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><description>We developed three daunorubicin (D1)-resistant sublines (ML1/I, II, III) from the human myelocytic cell line (ML1). These sublines were 28-, 70- and 162-fold more resistant than sensitive (ML1/S) cells to the cytotoxicity of D1 and were cross-resistant to adriamycin, epiadriamycin, actinomycin D, VP-16, VM26, and mitoxantrone. Steady-state levels of D1 in resistant sublines I and II, in the presence or absence of azide, were not significantly different from those of sensitive cells. However, the steady-state level of D1 in subline III was significantly increased in the presence of sodium azide. D1 efflux was minimal in ML1/S and resistant cells in the absenced of glucose. Addition of glucose enhanced D1 efflux only in subline III. Verapamil increased the cellular levels of D1 and inhibited its efflux from resistant III cells but not from ML1/S cells. Verapamil also greatly enhanced the cytotoxicity of D1 for sublines I, II, and III. The differences between sensitive and resistant cells in D1 uptake and retention seemed inadequate to cause 162-fold resistance and suggested other factors may be contributing to the development of resistance. In support of this hypothesis, daunorubicin reductase activity was significantly lower in resistant cells than in ML1/S cells. The greatest decrease in activity occurred at pH 8.5 which represents aldehyde reductases. Currently, we are investigating other possibilities for D1 metabolism, such as aglycone and free radical formation.</description><subject>Adult</subject><subject>Alcohol Oxidoreductases - analysis</subject><subject>Aldehyde Reductase</subject><subject>Aldo-Keto Reductases</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Biological Transport</subject><subject>Cell Line</subject><subject>Daunorubicin - metabolism</subject><subject>Daunorubicin - pharmacology</subject><subject>Drug Resistance</subject><subject>Drug Synergism</subject><subject>General aspects</subject><subject>Humans</subject><subject>Leukemia, Myeloid - metabolism</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Verapamil - pharmacology</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1986</creationdate><recordtype>article</recordtype><recordid>eNpFkE1Lw0AQhhdRaq1evAt78CREZzNJNzlqsSoUvOg5zH5EV5Js2d0c-u-NtNTLvAzvwww8jF0LuBcA8uFpDZAv81zKEzYXBeYZVAWesjlgUWSlhOKcXcT4AwCFQJyxGZZYY4VzplZ-SMGpMTk_cN9yE8YvngINcetD4jQYHqwZdaJoI0-eGxoHH0bltBumKrqYaNCWT9v32NPA-53tvN4lp7m2XRcv2VlLXbRXh1ywz_Xzx-o127y_vK0eN5lGIVJmZCsJllgKocAgSNRmGlAqQmuEAN2WmixJYUhUWFQEQlYgSUFdogJcsLv9XR18jMG2zTa4nsKuEdD8eWr-PU3wzR7ejqq35ogexEz97aGnqKlrJyHaxSMm63o5vcdfIKZwYQ</recordid><startdate>19860101</startdate><enddate>19860101</enddate><creator>VASANTHAKUMAR, G</creator><creator>AHMED, N. K</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19860101</creationdate><title>Contribution of drug transport and reductases to daunorubicin resistance in human myelocytic cells</title><author>VASANTHAKUMAR, G ; AHMED, N. K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-d7f7a063511b0d3073cd07305ba3ed110cf5caea71da18348a017807ab0953b03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1986</creationdate><topic>Adult</topic><topic>Alcohol Oxidoreductases - analysis</topic><topic>Aldehyde Reductase</topic><topic>Aldo-Keto Reductases</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Biological Transport</topic><topic>Cell Line</topic><topic>Daunorubicin - metabolism</topic><topic>Daunorubicin - pharmacology</topic><topic>Drug Resistance</topic><topic>Drug Synergism</topic><topic>General aspects</topic><topic>Humans</topic><topic>Leukemia, Myeloid - metabolism</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Verapamil - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>VASANTHAKUMAR, G</creatorcontrib><creatorcontrib>AHMED, N. K</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>VASANTHAKUMAR, G</au><au>AHMED, N. K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Contribution of drug transport and reductases to daunorubicin resistance in human myelocytic cells</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>1986-01-01</date><risdate>1986</risdate><volume>18</volume><issue>2</issue><spage>105</spage><epage>110</epage><pages>105-110</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><coden>CCPHDZ</coden><abstract>We developed three daunorubicin (D1)-resistant sublines (ML1/I, II, III) from the human myelocytic cell line (ML1). These sublines were 28-, 70- and 162-fold more resistant than sensitive (ML1/S) cells to the cytotoxicity of D1 and were cross-resistant to adriamycin, epiadriamycin, actinomycin D, VP-16, VM26, and mitoxantrone. Steady-state levels of D1 in resistant sublines I and II, in the presence or absence of azide, were not significantly different from those of sensitive cells. However, the steady-state level of D1 in subline III was significantly increased in the presence of sodium azide. D1 efflux was minimal in ML1/S and resistant cells in the absenced of glucose. Addition of glucose enhanced D1 efflux only in subline III. Verapamil increased the cellular levels of D1 and inhibited its efflux from resistant III cells but not from ML1/S cells. Verapamil also greatly enhanced the cytotoxicity of D1 for sublines I, II, and III. The differences between sensitive and resistant cells in D1 uptake and retention seemed inadequate to cause 162-fold resistance and suggested other factors may be contributing to the development of resistance. In support of this hypothesis, daunorubicin reductase activity was significantly lower in resistant cells than in ML1/S cells. The greatest decrease in activity occurred at pH 8.5 which represents aldehyde reductases. Currently, we are investigating other possibilities for D1 metabolism, such as aglycone and free radical formation.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>3539383</pmid><doi>10.1007/BF00262277</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0344-5704
ispartof Cancer chemotherapy and pharmacology, 1986-01, Vol.18 (2), p.105-110
issn 0344-5704
1432-0843
language eng
recordid cdi_crossref_primary_10_1007_BF00262277
source Springer Online Journal Archives (Through 1996)
subjects Adult
Alcohol Oxidoreductases - analysis
Aldehyde Reductase
Aldo-Keto Reductases
Antineoplastic agents
Biological and medical sciences
Biological Transport
Cell Line
Daunorubicin - metabolism
Daunorubicin - pharmacology
Drug Resistance
Drug Synergism
General aspects
Humans
Leukemia, Myeloid - metabolism
Medical sciences
Pharmacology. Drug treatments
Verapamil - pharmacology
title Contribution of drug transport and reductases to daunorubicin resistance in human myelocytic cells
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T02%3A09%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Contribution%20of%20drug%20transport%20and%20reductases%20to%20daunorubicin%20resistance%20in%20human%20myelocytic%20cells&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=VASANTHAKUMAR,%20G&rft.date=1986-01-01&rft.volume=18&rft.issue=2&rft.spage=105&rft.epage=110&rft.pages=105-110&rft.issn=0344-5704&rft.eissn=1432-0843&rft.coden=CCPHDZ&rft_id=info:doi/10.1007/BF00262277&rft_dat=%3Cpubmed_cross%3E3539383%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c311t-d7f7a063511b0d3073cd07305ba3ed110cf5caea71da18348a017807ab0953b03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/3539383&rfr_iscdi=true